Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT) | Aplastic Anemia & MDS International Foundation
Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)

Clinical Trial: NCT01812252

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This randomized clinical trial studies different chemotherapies in treating patients with myelodysplastic syndrome before donor stem cell transplant. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells, and may prevent the myelodysplastic syndrome from coming back after the transplant. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

Status: 
Recruiting
Study Date: 
Mon, 04/01/2013 to Thu, 04/01/2021
Bone Marrow Disease(s): 
  • chronic myelomonocytic leukaemia (CMML)
  • myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: Azacitidine Given IV or SC Other Names: 5 AZC 5-AC 5-Azacytidine 5-AZC Azacytidine Azacytidine, 5- Ladakamycin Mylosar U-18496 Vidaza Drug: Decitabine Given IV or SC Other Names: 5-Aza-2'-deoxycytidine Dacogen Decitabine for Injection Deoxyazacytidine Dezocitidine Other: Quality-of-Life Assessment Ancillary studies Other Name: Quality of Life Assessment